Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Pacritinib moving forwards for myelofibrosis

Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the results of PAC2013 (NCT03165734), a randomized phase II dose-finding study of pacritinib in patients with myelofibrosis (MF) who were intolerant of or failed to benefit from ruxolitinib. Results from the study include pharmacokinetic and pharmacodynamic analyses, used to identify the recommended dose of pacritinib for further study. The optimal dose identified was generally well tolerated and demonstrated clinical activity, particularly in patients with severe thrombocytopenia, and phase 3 study (PACIFICA) is upcoming. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.